ESMO 2021 journaal | Melanoom

Het belangrijkse ESMO-nieuws op het gebied van het melanoom wordt in dit journaal bediscussieerd door dr. Karijn Suijkerbuijk en prof. dr. Christian Blank. 

Zij bespreken de volgende studies:

1. Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial;
2. Adjuvant treatment for melanoma in clinical practice – trial versus reality;
3. Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon-gamma signature (IFN-γ sign): the DONIMI study;
4. MASTERKEY-265: A phase 3, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL);
5. SECOMBIT: the best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma. A phase II randomized study;
6. Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma;
7. Dutch advanced melanoma care in times of COVID-19. (Publicatie volgt binnenkort)

Bekijk hier het volledige overzicht van onze ESMO 2021 journaals en interviews.